Add to favorites

#Industry News

Promising Progress: Vaccine Against Eilat/Chikungunya Virus Shows Potential for Future Development

A single dose of the EILV/CHIKV vaccine triggers an exceptional T-cell response—setting a new benchmark for immune performance.

How Do Vaccines Work?
The exact mechanisms behind vaccine protection aren’t always fully understood—and that’s true for the insect-based chimeric alphavirus vaccine targeting Eilat (EILV)/chikungunya (CHIKV) virus. CHIKV can cause both acute and chronic infections in humans, making an effective vaccine essential.
In a recent study, researchers investigated how the EILV/CHIKV vaccine and the live-attenuated CHIKV181/25 vaccine activate immune pathways in cynomolgus macaques, shedding light on their mechanisms of action.

Fig 4 from article

Details

  • Skeiðarás 12, 210 Garðabær, Iceland
  • Star-Oddil